Supplemental imaging techniques improve cancer detection in women with dense breasts

In women with dense breasts (breasts with relatively low levels of fatty tissue) and a negative mammogram, supplemental imaging techniques detect early-stage cancers, with imaging techniques three times more effective than ultrasound, finds a phase 3 randomized control trial published in The Lancet.

Women with extremely dense breasts, about 10% of those aged 50-70 years in the UK, face a fourfold increased risk of breast cancer compared to those with the least dense breasts. Mammograms are less effective for detecting early-stage cancer in dense breasts, as the tissue can hide tumors on the breast x-rays. Previous studies have shown MRI and ultrasound are effective supplementary imaging methods, but this study is the first to compare them with contrast mammography in women with normal mammograms and dense breast tissue.

Over 9000 women in the UK with dense breasts and a negative mammogram were randomly allocated to one of three different supplementary techniques. The cancer detection rate for the imaging techniques was 1.7% (for a fast MRI) and 1.9% (for contrast mammography), whilst the cancer detection rate for the ultrasound group was 0.4%.

Authors highlight that although this study shows the scans can detect additional small cancers which are likely to save lives, further research is needed to confirm whether they could reduce the number of deaths due to breast cancer, to establish the risk of overdiagnosis and to estimate the cost benefit ratio of implementing a supplemental imaging strategy for breast cancer screening.

In addition to the relevance for the UK's breast cancer screening programme, this study has global implications for all countries where screening is undertaken for women with dense breast tissue."

Professor Fiona Gilbert, Lead Author, University of Cambridge (UK)

Source:
Journal reference:

Gilbert, F. J., et al. (2025). Comparison of supplemental breast cancer imaging techniques—interim results from the BRAID randomised controlled trial. The Lancet. doi.org/10.1016/S0140-6736(25)00582-3.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Does COVID increase the risk of Alzheimer’s disease?